Orris

Depression among adolescent

Reading File
Reading File
Running Command

cd /tmp/workspace/attachments/d47ba26e-ea9e-4770-8309-9046bfea3096 && python3 -c " import pdfplumber with pdfplumber.open('Part 3 -Behavioral and Psychiatric Disorders - Nelson 2024.pdf') as pdf: print('pages', len(pdf.pages)) full = [] for i,page in enumerate(pdf.pages): t = page.extract_text() or '' full.append(t) alltext = '\n'.join(full) print(len(alltext)) import re idxs = [m.start() for m in re.finditer(r'[Dd]epression', alltext)] print('num matches', len(idxs)) print(idxs[:20]) "

Finding Sources
Searching PubMed

"adolescent depression" AND treatment

Searching the Web

adolescent depression diagnosis treatment guidelines 2025

Running Command

cd /tmp/workspace/attachments/d47ba26e-ea9e-4770-8309-9046bfea3096 && python3 -c " import pdfplumber, re with pdfplumber.open('Part 3 -Behavioral and Psychiatric Disorders - Nelson 2024.pdf') as pdf: full = [] for page in pdf.pages: t = page.extract_text() or '' full.append(t) alltext = '\n'.join(full) # find likely chapter heading for m in re.finditer(r'DEPRESSIVE DISORDERS|Depressive Disorders|MAJOR DEPRESSIVE DISORDER', alltext): print(m.start(), repr(alltext[m.start()-40:m.start()+60])) "

Running Command

cd /tmp/workspace/attachments/d47ba26e-ea9e-4770-8309-9046bfea3096 && python3 -c " import pdfplumber, re with pdfplumber.open('Part 3 -Behavioral and Psychiatric Disorders - Nelson 2024.pdf') as pdf: full = [] for page in pdf.pages: t = page.extract_text() or '' full.append(t) alltext = '\n'.join(full) chunk = alltext[241500:266000] print(chunk) "

Running Command

cd /tmp/workspace/attachments/d47ba26e-ea9e-4770-8309-9046bfea3096 && python3 -c " import pdfplumber with pdfplumber.open('Part 3 -Behavioral and Psychiatric Disorders - Nelson 2024.pdf') as pdf: full = [] for page in pdf.pages: t = page.extract_text() or '' full.append(t) alltext = '\n'.join(full) chunk = alltext[266000:290000] print(chunk) "

Depression Among Adolescents

Based on the attached Nelson Pediatrics text (Part III, Chapter 39 "Mood Disorders," by Manak & Kim) and supplemented with current evidence.

Definition and Presentation

Major depressive disorder (MDD) requires a distinct period of at least 2 weeks with depressed or irritable mood and/or loss of interest/pleasure in almost all activities, present most of the day, nearly every day, plus associated vegetative/cognitive symptoms:
  • Changes in appetite, sleep, energy, and activity level
  • Impaired concentration
  • Feelings of worthlessness or guilt
  • Suicidal thoughts or actions
Severity is graded mild, moderate, or severe based on symptom burden and functional impairment. In adolescents specifically, energy, activity level, appetite, and sleep disturbances tend to be more prominent than in younger children, where irritability and somatic complaints predominate (children may also lack the cognitive/linguistic maturity to self-report symptoms, so depression is more often observed than reported).
Related depressive spectrum disorders include:
  • Persistent depressive disorder - depressed/irritable mood most days for ≥1 year in youth (vs. 2 years in adults), with milder cognitive symptoms (low self-esteem rather than worthlessness)
  • Disruptive mood dysregulation disorder (DMDD) - severe, frequent temper outbursts (≥3x/week) with persistent background irritability for ≥12 months, onset before age 10
  • Other specified/unspecified (subsyndromal) depressive disorder
(Nelson Textbook of Pediatrics, Ch. 39, "Mood Disorders")

Epidemiology

  • Current U.S. prevalence in ages 3-17: ~3.2%; lifetime prevalence rises to 4.9% (ages 6-17) and 12.8% (ages 12-17)
  • Male:female ratio is ~1:1 in childhood, shifting to 1:1.5-3.0 by adulthood (female predominance emerges in early adolescence)
  • Onset likelihood increases sharply with puberty; incidence peaks in the 20s
  • 5-10% of children/adolescents have subsyndromal depression

Etiology and Risk Factors

  • Heritability shown via monozygotic twin concordance (40-65%); 2-4 fold increased risk among first-degree relatives (bidirectional)
  • Biologic vulnerability: serotonergic dysfunction, HPA-axis abnormalities, difficult temperament, ruminative/self-devaluating cognitive style
  • Psychosocial risk factors (more influential in youth than adults): physical/sexual abuse, neglect, chronic illness, bullying/academic failure, social isolation, family discord, divorce, parental psychopathology
  • Protective factors: good family function, prosocial peer group, higher IQ, positive caregiver relationship, close supervision

Screening and Diagnosis

  • Routine screening question in primary care: asking about sad/angry mood directly
  • Standardized tools: PHQ-9, Beck Depression Inventory, Children's Depression Inventory, Mood and Feelings Questionnaire, Reynolds Adolescent Depression Scale, among others
  • USPSTF recommends universal depression screening in adolescents (not younger children) when adequate follow-up systems exist, though a Cochrane review found screening alone has little impact on outcomes without follow-up infrastructure
  • Targeted screening of high-risk groups (homeless youth, LGBTQ+ youth, juvenile justice/child welfare involvement) may be higher-yield than universal screening
Differential diagnosis must exclude: ASD, ADHD, bipolar disorder, anxiety, trauma-related and substance use disorders; medical conditions (hypothyroidism, Addison disease, autoimmune encephalitis, anemia, chronic fatigue); and medication effects (corticosteroids, beta-blockers, contraceptives, chemotherapy agents).
Comorbidity: 40-90% of depressed youth have another psychiatric disorder; up to 50% have ≥2 comorbidities. Anxiety disorders are most common, followed by ADHD, disruptive behavior, eating, and substance use disorders.

Treatment

Depression in youth responds substantially to placebo (50-60%) and nonspecific intervention (15-30%), so treatment intensity should be matched to severity.
Mild depression: guided self-help/watchful waiting with scheduled follow-up; behavioral activation (exercise, social engagement, hobbies), mindfulness, regular sleep schedule.
Persistent mild or moderate-severe depression:
  • Psychotherapy: CBT/behavioral activation and interpersonal therapy have the best evidence (modest effect sizes), typically 8-12 sessions
  • Pharmacotherapy: Fluoxetine and escitalopram are the only FDA-approved antidepressants for youth depression (fluoxetine alone approved for preadolescents). Paroxetine is not recommended (shown ineffective in children). All SSRIs carry a black-box warning for increased suicidal thinking in patients under 25, especially at treatment initiation and dose changes.
  • Adequate SSRI trial = 6-8 weeks at target dose; if first SSRI fails, switch to a second SSRI plus CBT (~50% response) vs. medication alone (~40%)
  • Treatment should continue 6-12 months given high recurrence risk; taper gradually (except fluoxetine, given its long half-life)
  • Ketamine/esketamine have shown efficacy in adult treatment-resistant depression but are not established pediatric therapies here
Level of care: most mild-moderate cases managed outpatient; inpatient care reserved for significant suicide risk, self-harm, inadequate family supervision, or need for comprehensive diagnostic clarification.

Clinical Course and Sequelae

  • Median episode duration: 5-8 months (clinical samples), 3-6 months (community samples)
  • Recurrence risk in adolescents: 50-70% within 5 years
  • Up to 20% of depressed adolescents later develop bipolar disorder (higher risk with genetic loading, psychotic features, or antidepressant-induced mania)
  • ~60% of youth with MDD report suicidal ideation; ~30% attempt suicide
  • Associated with substance abuse, impaired relationships, early pregnancy, and academic/occupational underachievement

Recent Evidence (2025)

A few recent systematic reviews/meta-analyses may refine specific treatment comparisons beyond what the textbook covers:
  • A 2025 network meta-analysis comparing antidepressant efficacy in adolescent depression (PMID: 40349006)
  • A 2025 meta-analysis on acceptance and commitment therapy for adolescent depression (PMID: 40458781)
  • A 2025 critique in BMJ Mental Health questioning comparability of the youth depression treatment evidence base and current guidelines (PMID: 39832835) - worth noting as it raises methodological concerns about how psychotherapy vs. medication trials are compared, which could nuance the "insufficient evidence to favor one modality" statement above
These don't overturn the core textbook framework but suggest the comparative-efficacy evidence for specific treatments is still evolving. If you want, I can go deeper into any specific area - diagnostic criteria tables, SSRI dosing/side effects, DMDD vs. bipolar differentiation, or the newer treatment-comparison literature.
This is a shared conversation. Sign in to Orris to start your own chat.